Benitec Biopharma this week announced that it has licensed its proprietary expressed RNAi technology to Regen BioPharma, a San Diego-based subsidiary of Bio-Matrix, for use in developing cancer vaccines.

Specifically, the license covers the use of Benitec’s technology to silence indoleamine 2,3 doxygenase in dendritic cells. According to Benitec, the target is associated with immune suppression and is overexpressed in certain cancers.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Nature this week: researchers classify pancreatic cancer into four subtypes using sequencing, and more.

Genotyping analysis of measles in Ontario indicates the strain there didn't originate from Disneyland or Europe.

The UK Medical Research Council says the proposed path of a new train line could affect research at the Francis Crick Institute.

The House of Lords in the UK approves a bill to allow mitochondrial donation.